Autoimmune retinopathy (AIR) is a group of rare autoimmune disorders causing retinal degeneration, characterized by rapid vision deterioration linked to circulating anti-retinal autoantibodies (ARAs). The spectrum includes paraneoplastic forms—cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR)—and a nonparaneoplastic variant (npAIR). Diagnosis is challenging due to overlapping phenotypes with inherited retinal dystrophies, absent standardized diagnostic criteria, and limited availability of specialized serological testing. No international consensus on treatment protocols exists; immunosuppression remains the mainstay of therapy.
Ask a research question about Autoimmune Retinopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Autoimmune Retinopathy
creation_date: "2026-06-19T00:00:00Z"
description: >-
Autoimmune retinopathy (AIR) is a group of rare autoimmune disorders causing retinal
degeneration, characterized by rapid vision deterioration linked to circulating
anti-retinal autoantibodies (ARAs). The spectrum includes paraneoplastic forms—cancer-associated
retinopathy (CAR) and melanoma-associated retinopathy (MAR)—and a
nonparaneoplastic variant (npAIR). Diagnosis is challenging due to overlapping phenotypes
with inherited retinal dystrophies, absent standardized diagnostic criteria, and limited
availability of specialized serological testing. No international consensus on treatment
protocols exists; immunosuppression remains the mainstay of therapy.
category: Complex
disease_term:
preferred_term: Autoimmune Retinopathy
term:
id: MONDO:0100014
label: autoimmune retinopathy
parents:
- retinopathy
has_subtypes:
- name: CAR
display_name: Cancer-Associated Retinopathy (CAR)
subtype_term:
preferred_term: Cancer-Associated Retinopathy
term:
id: MONDO:0019112
label: cancer-associated retinopathy
description: >-
Autoimmune retinopathy triggered by systemic malignancy (most commonly small-cell
lung cancer, gynecological tumors, or breast cancer) in which tumor antigens that
share epitopes with retinal proteins elicit anti-retinal antibodies, leading to
photoreceptor degeneration.
evidence:
- reference: PMID:41003888
reference_title: "Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most frequently associated malignancies were lung cancers (notably
small-cell lung carcinoma), gynecological cancers, and melanoma.
explanation: >-
A systematic review of 147 paraneoplastic ocular syndrome patients. The
reported malignancy frequencies are aggregated across all six paraneoplastic
ocular syndromes, not the 53 CAR patients alone - melanoma appears on the list
largely through the 22 MAR patients, and breast cancer, named in this subtype
description, is not in the quoted sentence at all. The quote therefore supports
lung and gynecological tumours as leading associations for the syndrome group
that CAR belongs to, not a CAR-specific ranking.
- reference: PMID:16444517
reference_title: "Recoverin as a cancer-retina antigen."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The aberrant expression of recoverin in cancer cells and the presence of
autoantibodies against recoverin are essential for the occurrence of cancer-associated
retinopathy, which finally results in the apoptosis of photoreceptor
cells.
explanation: >-
Defines the CAR subtype: tumor-aberrant expression of a retinal antigen
drives autoantibodies that destroy photoreceptors.
- name: MAR
display_name: Melanoma-Associated Retinopathy (MAR)
subtype_term:
preferred_term: Melanoma-Associated Retinopathy
term:
id: MONDO:0023868
label: melanoma associated retinopathy
description: >-
Autoimmune retinopathy arising in patients with cutaneous or uveal melanoma.
Melanoma cells express antigens cross-reactive with bipolar cell antigens
(principally TRPM1), leading to autoantibodies that impair retinal ON-bipolar cell
signaling and cause night-blindness and shimmering photopsias.
evidence:
- reference: PMID:38946992
reference_title: "Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated Retinopathy Patient."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MAR is caused by autoantibodies targeting TRPM1, an ion channel found in
melanocytes and retinal ON-bipolar cells (ON-BCs).
explanation: >-
States the defining feature of this subtype: a melanocyte antigen shared with
retinal ON-bipolar cells, which is what makes melanoma the trigger.
- reference: PMID:34562437
reference_title: >-
Broad locations of antigenic regions for anti-TRPM1 autoantibodies in
paraneoplastic retinopathy with retinal ON bipolar cell dysfunction.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cancer-associated retinal ON bipolar cell dysfunction (CARBD), which includes
melanoma-associated retinopathy (MAR), has been reported to be caused by
autoantibodies against the molecules expressed in ON bipolar cells, including TRPM1.
explanation: >-
Defines the MAR subtype by anti-TRPM1 autoantibodies acting on retinal
ON bipolar cells.
- name: npAIR
display_name: Nonparaneoplastic Autoimmune Retinopathy (npAIR)
description: >-
Autoimmune retinopathy occurring without an identifiable underlying malignancy.
Similar anti-retinal autoantibodies arise spontaneously, possibly in association
with concurrent systemic autoimmune disease. npAIR tends to
affect younger patients and females more often than the paraneoplastic variants.
Diagnosis requires exclusion of occult malignancy and inherited retinal dystrophy.
evidence:
- reference: PMID:40824502
reference_title: "Diagnosis and treatment of autoimmune retinopathy: review of current approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Non-paraneoplastic AIR patients may be younger on average than paraneoplastic AIR
patients and may have a higher likelihood of being female and having a history of
autoimmune disease.
explanation: >-
Distinguishes the nonparaneoplastic subtype from the paraneoplastic forms
by age, sex, and coexisting autoimmune disease.
pathophysiology:
- name: Anti-Retinal Antibody Production via Molecular Mimicry
description: >-
In CAR, tumor cells aberrantly express retinal proteins (most prominently recoverin/
RCVRN) or proteins sharing epitopes with retinal antigens, and the resulting immune
response drives B-cell production of anti-retinal IgG autoantibodies (molecular
mimicry). The exact mechanisms by which ocular immune privilege breaks down and
self-tolerance is lost remain unknown. In MAR, melanoma cells express TRPM1
(transient receptor potential cation channel subfamily M member 1), which is also
expressed in retinal ON-bipolar cells; the resulting anti-TRPM1 antibodies disrupt
bipolar-cell signaling. In nonparaneoplastic AIR (npAIR), the inciting trigger is
unknown but similar anti-retinal autoantibodies arise without detectable malignancy,
possibly in association with concurrent systemic autoimmune disease.
downstream:
- target: Photoreceptor and Bipolar Cell Injury by Autoantibodies
causal_link_type: DIRECT
description: >-
Anti-retinal autoantibodies cross the blood-retinal barrier and bind their
cognate retinal antigens, initiating antibody-mediated retinal cell injury.
evidence:
- reference: PMID:16444517
reference_title: "Recoverin as a cancer-retina antigen."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The aberrant expression of recoverin in cancer cells and the presence of
autoantibodies against recoverin are essential for the occurrence of cancer-associated
retinopathy, which finally results in the apoptosis of photoreceptor
cells.
explanation: >-
Places autoantibody production upstream of photoreceptor apoptosis,
which is the edge asserted here.
- reference: PMID:38946992
reference_title: "Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated Retinopathy Patient."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The visual symptoms arise when TRPM1 autoantibodies enter ON-BCs and block
the function of TRPM1, thus detection of TRPM1 autoantibodies in patient
serum is a key criterion in diagnosing MAR.
explanation: >-
States the antibody-to-cell-injury step explicitly for the MAR arm:
circulating autoantibody must reach and enter the target retinal neuron to
produce dysfunction. The same report finds intraocular corticosteroid
relieves symptoms despite persistently high circulating antibody, which is
why antibody access across the blood-retinal barrier, not titre alone, is
modeled as the causal step.
- reference: PMID:40824502
reference_title: "Diagnosis and treatment of autoimmune retinopathy: review of current approaches."
supports: REFUTE
evidence_source: HUMAN_CLINICAL
snippet: >-
The spectrum includes primary autoimmune diseases and associations with
retinitis pigmentosa or various malignancies, raising questions about the
causative role of antibodies.
explanation: >-
Cuts against this edge rather than supporting it. The 2025 review records
that the pathogenicity of anti-retinal antibodies (anti-recoverin in
particular) is disputed, so the antibody-to-injury link is curated as the
prevailing model, not a settled fact. Retained deliberately alongside the
supporting items so the dispute is visible on the edge.
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: CD4-positive T cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
biological_processes:
- preferred_term: humoral immune response
term:
id: GO:0006959
label: humoral immune response
modifier: INCREASED
- preferred_term: humoral immune response mediated by circulating immunoglobulin
term:
id: GO:0002455
label: humoral immune response mediated by circulating immunoglobulin
modifier: INCREASED
evidence:
- reference: PMID:40824502
reference_title: "Diagnosis and treatment of autoimmune retinopathy: review of current approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
AIR comprises a group of rare autoimmune disorders causing retinal degeneration,
characterized by rapid vision deterioration linked to circulating anti-retinal
autoantibodies (ARAs).
explanation: >-
Establishes circulating anti-retinal autoantibodies as the defining pathogenic
feature common to all AIR subtypes.
- reference: PMID:16444517
reference_title: "Recoverin as a cancer-retina antigen."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The aberrant expression of recoverin in cancer cells and the presence of
autoantibodies against recoverin are essential for the occurrence of cancer-associated
retinopathy, which finally results in the apoptosis of photoreceptor
cells.
explanation: >-
Mechanistically links tumor-aberrant expression of recoverin to autoantibody
production in CAR, directly supporting the molecular mimicry model.
- reference: PMID:34562437
reference_title: >-
Broad locations of antigenic regions for anti-TRPM1 autoantibodies in
paraneoplastic retinopathy with retinal ON bipolar cell dysfunction.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cancer-associated retinal ON bipolar cell dysfunction (CARBD), which includes
melanoma-associated retinopathy (MAR), has been reported to be caused by
autoantibodies against the molecules expressed in ON bipolar cells, including TRPM1.
explanation: >-
Demonstrates TRPM1 as the primary target antigen in MAR-related ON bipolar cell
dysfunction, confirming the molecular mimicry mechanism for the MAR subtype.
- name: Photoreceptor and Bipolar Cell Injury by Autoantibodies
description: >-
Anti-retinal autoantibodies penetrate the outer retina and cause cell-type-specific
injury. In CAR, anti-recoverin antibodies target recoverin, the calcium-binding
protein that normally controls rhodopsin phosphorylation by inhibiting rhodopsin
kinase, and their presence culminates in photoreceptor apoptosis. Anti-alpha-enolase
antibodies are also among the most commonly detected autoantibodies in CAR. In MAR,
anti-TRPM1 antibodies enter ON-bipolar cells and block TRPM1 channel function,
producing a characteristic electronegative ERG. The result is progressive, largely
irreversible photoreceptor and inner retinal neuronal loss that clinically mimics
inherited retinal dystrophies.
downstream:
- target: Visual Field Loss
causal_link_type: DIRECT
description: >-
Topographic photoreceptor degeneration produces corresponding scotomas and
progressive visual field constriction.
evidence:
- reference: PMID:35571681
reference_title: "Autoimmune Retinopathy, Testing, and Its Controversies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
AIRs are a group of inflammatory conditions affecting the retina characterized
by progressive unexplained visual loss, abnormalities and contraction in visual
fields, photoreceptor and electroretinographic dysfunction, and the presence of
circulating anti-retinal antibodies.
explanation: >-
Contraction of visual fields is named alongside photoreceptor
dysfunction, supporting field loss as a consequence of retinal
cell injury.
- target: Nyctalopia
causal_link_type: DIRECT
description: >-
Preferential rod photoreceptor or ON-bipolar cell injury causes night blindness.
evidence:
- reference: PMID:38946992
reference_title: "Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated Retinopathy Patient."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome
associated with cutaneous metastatic melanoma in which patients develop
vision deficits that include reduced night vision, poor contrast
sensitivity, and photopsia. MAR is caused by autoantibodies targeting
TRPM1, an ion channel found in melanocytes and retinal ON-bipolar cells
(ON-BCs).
explanation: >-
Attributes reduced night vision to ON-bipolar cell TRPM1 blockade, which is
the mechanism this edge asserts. The direct evidence is for the MAR
(ON-bipolar) arm; the rod-photoreceptor route named in the edge description
is inferred from the shared rod-pathway anatomy rather than cited here.
- reference: PMID:34562437
reference_title: >-
Broad locations of antigenic regions for anti-TRPM1 autoantibodies in
paraneoplastic retinopathy with retinal ON bipolar cell dysfunction.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cancer-associated retinal ON bipolar cell dysfunction (CARBD), which includes
melanoma-associated retinopathy (MAR), has been reported to be caused by
autoantibodies against the molecules expressed in ON bipolar cells, including TRPM1.
explanation: >-
Establishes autoantibody-mediated ON bipolar cell dysfunction, the
lesion underlying night blindness in MAR. Supports the edge only
indirectly: the abstract establishes the ON bipolar cell lesion but
does not state the nyctalopia outcome itself.
- target: Photopsias
causal_link_type: DIRECT
description: >-
Aberrant photoreceptor or bipolar cell depolarization generates positive visual
phenomena.
evidence:
- reference: PMID:38946992
reference_title: "Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated Retinopathy Patient."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
patients develop vision deficits that include reduced night vision, poor
contrast sensitivity, and photopsia
explanation: >-
Places photopsia among the vision deficits produced by anti-TRPM1
ON-bipolar cell blockade in MAR. This is a single longitudinal case report,
so it establishes the association, not its frequency.
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
cell_types:
- preferred_term: retinal rod cell
term:
id: CL:0000604
label: retinal rod cell
- preferred_term: retinal cone cell
term:
id: CL:0000573
label: retinal cone cell
- preferred_term: retinal ON bipolar cell
term:
id: CL:0000749
label: ON-bipolar cell
biological_processes:
- preferred_term: photoreceptor apoptosis
term:
id: GO:0051402
label: neuron apoptotic process
modifier: INCREASED
evidence:
- reference: PMID:16444517
reference_title: "Recoverin as a cancer-retina antigen."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The aberrant expression of recoverin in cancer cells and the presence of
autoantibodies against recoverin are essential for the occurrence of cancer-associated
retinopathy, which finally results in the apoptosis of photoreceptor
cells.
explanation: >-
Links anti-recoverin autoantibody activity in CAR to photoreceptor apoptosis,
the cell injury asserted by this node.
- reference: PMID:35571681
reference_title: "Autoimmune Retinopathy, Testing, and Its Controversies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
AIRs are a group of inflammatory conditions affecting the retina characterized
by progressive unexplained visual loss, abnormalities and contraction in visual
fields, photoreceptor and electroretinographic dysfunction, and the presence of
circulating anti-retinal antibodies.
explanation: >-
Links circulating anti-retinal antibodies to photoreceptor dysfunction and
electroretinographic abnormalities, supporting antibody-mediated retinal injury.
- reference: PMID:37958272
reference_title: >-
Structural and Functional Changes in Non-Paraneoplastic Autoimmune Retinopathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Structural changes at the baseline were detected in 14 of 16 (87.5%) eyes on
WAFP and WAFAF and 13 of 16 (81.2%) eyes on SD-OCT.
explanation: >-
Longitudinal cohort data quantifying high rates of structural retinal injury
in npAIR using multimodal imaging, consistent with progressive autoantibody-mediated
photoreceptor destruction.
phenotypes:
- category: Ophthalmologic
name: Visual Field Loss
description: >-
Progressive constriction of visual fields with ring scotomas or diffuse loss,
developing over weeks to months. In CAR, loss is typically rapid and bilateral;
in MAR, central vision may be relatively preserved with more prominent nyctalopia
and peripheral field defects. A systematic review of paraneoplastic ocular
syndromes found visual impairment to be bilateral in over 90% of cases.
phenotype_term:
preferred_term: Visual field defect
term:
id: HP:0001123
label: Visual field defect
clinical_course: PROGRESSIVE
evidence:
- reference: PMID:35571681
reference_title: "Autoimmune Retinopathy, Testing, and Its Controversies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
AIRs are a group of inflammatory conditions affecting the retina characterized
by progressive unexplained visual loss, abnormalities and contraction in visual
fields, photoreceptor and electroretinographic dysfunction, and the presence of
circulating anti-retinal antibodies.
explanation: >-
Identifies progressive visual field contraction as a defining clinical feature
of the entire AIR spectrum.
- reference: PMID:41003888
reference_title: >-
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis
and outcomes (2010-2023).
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Visual impairment was bilateral in over 90% of cases.
explanation: >-
Systematic review of 147 paraneoplastic ocular syndrome patients (including
53 CAR and 22 MAR) reports bilateral visual impairment in over 90% of the
pooled cases across all six syndromes reviewed.
- category: Ophthalmologic
name: Decreased Visual Acuity
description: >-
Reduction in best-corrected visual acuity that may be moderate to severe as disease
progresses, particularly in CAR with macular involvement. Rapid vision deterioration
is a cardinal presenting symptom.
phenotype_term:
preferred_term: Reduced visual acuity
term:
id: HP:0007663
label: Reduced visual acuity
evidence:
- reference: PMID:40824502
reference_title: >-
Diagnosis and treatment of autoimmune retinopathy: review of current approaches.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
AIR comprises a group of rare autoimmune disorders causing retinal degeneration,
characterized by rapid vision deterioration linked to circulating anti-retinal
autoantibodies (ARAs).
explanation: >-
Establishes rapid vision deterioration—including reduced visual acuity—as a
primary and defining clinical presentation of AIR.
- reference: PMID:41029312
reference_title: >-
Autoimmune retinopathy in patients with myasthenia gravis: cases series and
literature review.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The main ocular manifestations of AIR were bilateral, subacute, painless
vision loss.
explanation: >-
Clinical case series confirms bilateral subacute visual acuity loss as the
dominant presenting complaint in AIR.
- category: Ophthalmologic
name: Nyctalopia
description: >-
Night blindness is a prominent early feature, particularly in MAR where anti-TRPM1
antibodies target ON-bipolar cells and impair scotopic signal processing, and in CAR
where rod photoreceptors are preferentially affected initially.
phenotype_term:
preferred_term: Nyctalopia
term:
id: HP:0000662
label: Nyctalopia
evidence:
- reference: PMID:38946992
reference_title: >-
Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated
Retinopathy Patient.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
patients develop vision deficits that include reduced night vision, poor
contrast sensitivity, and photopsia
explanation: >-
Reduced night vision is enumerated among the defining visual deficits of MAR,
directly supporting nyctalopia as an AIR phenotype.
- reference: PMID:33796514
reference_title: "Cancer-Associated Retinopathy due to Clear Cell Renal Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
An 84-year-old female presented with bilateral scotomas and progressive
nyctalopia over 1 year.
explanation: >-
CAR case report documenting progressive nyctalopia as a presenting symptom.
- reference: PMID:41029312
reference_title: >-
Autoimmune retinopathy in patients with myasthenia gravis: cases series and
literature review.
supports: SUPPORT
directness: INDIRECT
evidence_source: HUMAN_CLINICAL
snippet: >-
Electroretinography (ERG) showed dysfunction of rod and cone cell.
explanation: >-
Rod ERG dysfunction is an electrophysiological correlate consistent with
night blindness, but this case series does not report nyctalopia as a
symptom, so the inference to the clinical phenotype is indirect.
- category: Ophthalmologic
name: Photopsias
description: >-
Flickering, shimmering, or flashing lights (photopsias) are a characteristic
early symptom, especially in MAR where anti-TRPM1 antibodies block ON-bipolar cell
signaling. Photopsias may also arise from ectopic photoreceptor excitation in CAR.
phenotype_term:
preferred_term: Photopsia
term:
id: HP:0030786
label: Photopsia
evidence:
- reference: PMID:38946992
reference_title: >-
Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated
Retinopathy Patient.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
patients develop vision deficits that include reduced night vision, poor
contrast sensitivity, and photopsia
explanation: >-
MAR case report directly enumerates photopsia as a defining visual symptom
of melanoma-associated retinopathy, caused by TRPM1 autoantibody-mediated
ON-bipolar cell dysfunction.
- category: Ophthalmologic
name: Abnormal Electroretinogram
description: >-
Electroretinography (ERG) characteristically shows reduced or extinguished responses.
In CAR, both scotopic (rod) and photopic (cone) responses are diminished. In MAR,
there is a distinctive electronegative ERG with reduced b-wave amplitude at preserved
a-wave, reflecting selective ON-bipolar cell dysfunction. ERG and anti-retinal
antibody testing are reported in over 80% of npAIR publications, making ERG the
most widely used diagnostic tool.
phenotype_term:
preferred_term: Abnormal electroretinogram
term:
id: HP:0000512
label: Abnormal electroretinogram
evidence:
- reference: PMID:37958272
reference_title: >-
Structural and Functional Changes in Non-Paraneoplastic Autoimmune Retinopathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Functional changes were detected in 14 of 16 (87.5%) eyes on GVF, 15 of 16
(93.7%) eyes on MP, and 11 of 16 (68.7%) eyes on full-field electroretinogram
(ff-ERG). Multifocal electroretinogram (mf-ERG) and visual evoked potential
(VEP) tests were performed in 14 eyes, of which 12 (85.7%) and 14 (100%) of
the eyes demonstrated functional abnormalities, respectively, at baseline.
explanation: >-
Longitudinal cohort data demonstrates high prevalence of ERG abnormalities
in npAIR, confirming electroretinographic dysfunction as a core functional
phenotype of the disease.
- reference: PMID:41400833
reference_title: >-
Nonparaneoplastic Autoimmune Retinopathy: Scoping Review and Suggested
Reporting Guidelines.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Over 80% of publications reported electroretinography and anti-retinal antibody
testing for diagnosis of npAIR.
explanation: >-
Scoping review of 77 publications confirms that abnormal ERG is the primary
functional phenotype universally measured for npAIR diagnosis and monitoring.
reports_on:
- target: Photoreceptor and Bipolar Cell Injury by Autoantibodies
relationship: READOUT_OF
endpoint_context: DIAGNOSTIC
interpretation: >-
Loss of photoreceptor and bipolar cell function reduces ERG amplitudes; MAR
produces a distinctive electronegative waveform.
- category: Ophthalmologic
name: Color Vision Defect
description: >-
Acquired dyschromatopsia may occur due to cone photoreceptor involvement,
particularly in CAR where both rod and cone photoreceptors are affected by
anti-recoverin or anti-alpha-enolase autoantibodies.
phenotype_term:
preferred_term: Color vision defect
term:
id: HP:0000551
label: Color vision defect
evidence:
- reference: PMID:33796514
reference_title: "Cancer-Associated Retinopathy due to Clear Cell Renal Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Best-corrected visual acuity was 20/50 in both eyes with reduced color vision.
explanation: >-
CAR case report documenting reduced color vision, supporting acquired
dyschromatopsia as an AIR phenotype.
- reference: PMID:40986840
reference_title: >-
A 10-year-old Girl with an 8-Month History of Progressive Photophobia and
Hemeralopia.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A 10-year-old female presented with decreased visual acuity, light sensitivity,
and decreased color vision over the past 8 months with no improvement upon
refraction.
explanation: >-
Nonparaneoplastic AIR case report documenting decreased color vision at
presentation, showing dyschromatopsia also occurs outside the paraneoplastic
forms.
treatments:
- name: Corticosteroids and Steroid-Sparing Immunosuppression
description: >-
First-line systemic immunosuppression with oral prednisone, often followed by
or combined with conventional steroid-sparing agents (mycophenolate mofetil,
azathioprine, cyclosporine, or methotrexate). Meta-analysis of 12 studies
demonstrates that systemic therapy significantly slows progressive visual acuity
loss, visual field loss, and cystoid macular edema. Response is variable; some
patients stabilize while others progress despite treatment. No randomized controlled
trials exist and no universally accepted protocol has been established.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: prednisone
term:
id: CHEBI:8382
label: prednisone
- preferred_term: mycophenolate mofetil
term:
id: CHEBI:8764
label: mycophenolate mofetil
- preferred_term: azathioprine
term:
id: CHEBI:2948
label: azathioprine
- preferred_term: cyclosporine
term:
id: NCIT:C406
label: Cyclosporine
- preferred_term: methotrexate
term:
id: CHEBI:44185
label: methotrexate
therapeutic_modality: SMALL_MOLECULE
evidence:
- reference: PMID:39669695
reference_title: >-
Clinical Outcomes of Therapeutic Interventions for Autoimmune Retinopathy:
A Meta-analysis and Systematic Review.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Systemic therapy significantly reduces the risk of progressive visual loss.
explanation: >-
Meta-analysis of 12 studies is the strongest available evidence supporting
systemic corticosteroids and steroid-sparing agents as first-line therapy;
the CONCLUSION confirms significant slowing of progressive visual loss.
- reference: PMID:40824502
reference_title: >-
Diagnosis and treatment of autoimmune retinopathy: review of current approaches.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The lack of randomized controlled trials and a universally accepted treatment
protocol for AIR further contribute to uncertainties in its management.
explanation: >-
Contextualizes the SUPPORT evidence—current recommendations derive from case
series and meta-analyses because RCTs are lacking.
- name: Intravenous Immunoglobulin (IVIG)
description: >-
High-dose IVIG has been used in patients who fail corticosteroids or as add-on
therapy for refractory AIR, with the aim of neutralizing circulating pathogenic
anti-retinal antibodies. Evidence is limited to case reports and small series;
no randomized controlled trials exist.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: intravenous immunoglobulin
term:
id: NCIT:C2701
label: Therapeutic Immune Globulin
therapeutic_modality: OTHER
- name: Intravitreal Corticosteroids
description: >-
Local intravitreal injections of sustained-release corticosteroids (e.g.,
dexamethasone implant, triamcinolone) provide targeted retinal immunosuppression,
reducing inflammatory damage to photoreceptors and bipolar cells. Meta-analysis
data support that local therapy significantly reduces progressive visual loss and
retinal morphology loss.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: dexamethasone
term:
id: CHEBI:41879
label: dexamethasone
- preferred_term: triamcinolone
term:
id: CHEBI:9667
label: triamcinolone
therapeutic_modality: SMALL_MOLECULE
evidence:
- reference: PMID:39669695
reference_title: >-
Clinical Outcomes of Therapeutic Interventions for Autoimmune Retinopathy:
A Meta-analysis and Systematic Review.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Local therapy significantly decreases the risk of both progressive visual loss
and retinal morphology loss, and therefore may offer precise targeting of the
retina.
explanation: >-
Meta-analysis of 12 studies provides quantitative evidence that local therapy
significantly reduces progressive visual loss and retinal morphology loss. The
abstract does not break the local-therapy arm out by agent, so this is
class-level support for local (intravitreal) treatment rather than a
corticosteroid-specific result.
- reference: PMID:38946992
reference_title: >-
Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated
Retinopathy Patient.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
intraocular dexamethasone treatment alleviates MAR visual symptoms despite high
levels of circulating TRPM1 autoantibodies
explanation: >-
MAR case report in which slow-release intraocular corticosteroid (dexamethasone)
treatment alleviated visual symptoms, directly supporting intravitreal
corticosteroid use in AIR.
- name: Rituximab
description: >-
Anti-CD20 B-cell depletion therapy targeting the autoantibody-producing B-cell
compartment. Individual AIR case reports describe stabilization or improvement of
visual function with rituximab. Meta-analysis demonstrates significant reduction
in both functional and morphological retinal changes with biologic therapy as a
class.
therapeutic_modality: MONOCLONAL_ANTIBODY
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: rituximab
term:
id: NCIT:C1702
label: Rituximab
evidence:
- reference: PMID:39669695
reference_title: >-
Clinical Outcomes of Therapeutic Interventions for Autoimmune Retinopathy:
A Meta-analysis and Systematic Review.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Biologics significantly reduce both functional and morphological retinal changes.
explanation: >-
Meta-analysis shows the biologic class significantly reduces both functional
visual loss and morphological retinal changes. This is class-level evidence
relevant to rituximab, not a rituximab-specific result.
- reference: PMID:40986840
reference_title: >-
A 10-year-old Girl with an 8-Month History of Progressive Photophobia and
Hemeralopia.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Upon detection of anti-retinal antibodies, treatment was initiated with
stabilization and improvement of visual acuity and ERG responses with
rituximab treatment.
explanation: >-
Nonparaneoplastic AIR case report in which rituximab treatment was followed
by stabilization and improvement of visual acuity and ERG responses,
providing rituximab-specific clinical support.
- reference: PMID:40862484
reference_title: "Update on autoimmune retinopathy: diagnosis and management."
supports: NO_EVIDENCE
evidence_source: HUMAN_CLINICAL
snippet: >-
Advances in biomarkers and precision immunotherapy may improve diagnosis
and outcomes.
explanation: >-
Forward-looking closing line of a review, anticipating that future biomarker
and precision-immunotherapy work may improve diagnosis and outcomes. It names
no agent, reports no outcome, and makes no claim about rituximab, so it does
not bear on this treatment claim either way; the rituximab case report and the
biologic-class meta-analysis above carry the support. Retained for the
review's framing of where the field is headed, not as evidence for the drug.
classifications:
harrisons_chapter:
- classification_value: IMMUNE_RHEUMATOLOGIC
evidence:
- reference: PMID:40824502
reference_title: "Diagnosis and treatment of autoimmune retinopathy: review of current approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
AIR comprises a group of rare autoimmune disorders causing retinal degeneration,
characterized by rapid vision deterioration linked to circulating anti-retinal
autoantibodies (ARAs).
explanation: >-
The review characterises AIR as a group of autoimmune disorders driven
by circulating autoantibodies, placing it in Harrison's Immune-Mediated,
Inflammatory, and Rheumatologic Part. Note that the Harrison's Part
vocabulary has no ophthalmology Part, so the immune Part is also the
most specific organ-system home available for this entity.
notes: >-
AIR is an antibody-mediated autoimmune disorder; the anti-retinal autoantibody
response is the defining mechanism across all three subtypes.
- classification_value: ONCOLOGY_HEMATOLOGY
notes: >-
The paraneoplastic subtypes (CAR and MAR) are triggered by an underlying
malignancy and may be the presenting sign of an occult tumour, so AIR also
belongs with the paraneoplastic syndromes Harrison's covers in oncology.
evidence:
- reference: PMID:40824502
reference_title: "Diagnosis and treatment of autoimmune retinopathy: review of current approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The spectrum includes primary autoimmune diseases and associations with
retinitis pigmentosa or various malignancies
explanation: >-
The cancer- and melanoma-associated subtypes are paraneoplastic
syndromes of systemic malignancy, and the classification guidance
admits an organ-system Part specifically for organ-specific
paraneoplastic syndromes.
clinical_trials: []
datasets:
- accession: geo:GSE117751
title: NanoString comparison of immune gene expression between AIR patients, RP patients and controls
description: Autoimmune retinopathy patient whole blood mRNA was compared to patients with retinitis pigmentosa and non-eye disease controls.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: MICROARRAY
sample_count: 42
publication: PMID:30271775
notes: Identified by GEO DataSets index search for Autoimmune Retinopathy (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
references:
- reference: PMID:40824502
title: "Diagnosis and treatment of autoimmune retinopathy: review of current approaches."
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
AIR comprises a group of rare autoimmune disorders causing retinal degeneration,
characterized by rapid vision deterioration linked to circulating anti-retinal
autoantibodies (ARAs).
supporting_text: >-
AIR comprises a group of rare autoimmune disorders causing retinal
degeneration, characterized by rapid vision deterioration linked to
circulating anti-retinal autoantibodies (ARAs).
- reference: PMID:40862484
title: "Update on autoimmune retinopathy: diagnosis and management."
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
AIR includes paraneoplastic forms—such as cancer-associated retinopathy (CAR)
and melanoma-associated retinopathy (MAR)—as well as a nonparaneoplastic (np)
variant (npAIR).
supporting_text: >-
AIR includes paraneoplastic forms - such as cancer-associated retinopathy
(CAR) and melanoma-associated retinopathy (MAR) - as well as a
nonparaneoplastic (np) variant (npAIR).
- reference: PMID:39669695
title: >-
Clinical Outcomes of Therapeutic Interventions for Autoimmune Retinopathy:
A Meta-analysis and Systematic Review.
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
Systemic therapy slows VA loss (RR = 0.04), VF loss (RR = 0.01), and CME
(RR = 0.02).
supporting_text: >-
Systemic therapy slows VA loss (risk ratio [RR] = 0.04, 95% confidence
interval [0.00, 0.91], P = 0.04), VF loss (RR = 0.01, 95% confidence
interval [0.00, 0.14], P = 0.0007), and CME (RR = 0.02, 95% confidence
interval [0.00, 0.34], P = 0.007).
- statement: >-
Biologics slow VA loss (RR = 0.28), VF loss (RR = 0.25), and CRT loss
(RR = 0.19).
supporting_text: >-
Biologics slow VA loss (RR = 0.28, 95% confidence interval [0.12, 0.65],
P = 0.003), VF loss (RR = 0.25, 95% confidence interval [0.15, 0.42],
P < 0.00001), and CRT loss (RR = 0.19, 95% confidence interval [0.04, 0.79],
P = 0.02).
- reference: PMID:41003888
title: >-
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis
and outcomes (2010-2023).
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
Visual impairment was bilateral in over 90% of cases across the six
paraneoplastic ocular syndromes reviewed; the most frequent malignancies
were lung, gynecological, and melanoma.
supporting_text: >-
Visual impairment was bilateral in over 90% of cases. The most frequently
associated malignancies were lung cancers (notably small-cell lung
carcinoma), gynecological cancers, and melanoma.
- statement: >-
Visual prognosis was especially poor in CAR, with 49.1% of patients
experiencing worsening vision.
supporting_text: >-
Visual prognosis varied but was especially poor in CAR, for which 49.1% of
patients experienced worsening vision.
- reference: PMID:41400833
title: >-
Nonparaneoplastic Autoimmune Retinopathy: Scoping Review and Suggested Reporting
Guidelines.
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
Over 80% of publications reported electroretinography and anti-retinal antibody
testing for diagnosis of npAIR.
supporting_text: >-
Over 80% of publications reported electroretinography and anti-retinal
antibody testing for diagnosis of npAIR.
- statement: >-
The scoping review covered 755 total npAIR cases across 77 publications
(36 case reports and 41 case series).
supporting_text: >-
36 case reports and 41 case series met eligibility criteria (755 total
cases).
- reference: PMID:37958272
title: >-
Structural and Functional Changes in Non-Paraneoplastic Autoimmune Retinopathy.
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
Structural changes were detected at baseline in 87.5% of npAIR eyes on
wide-angle imaging.
supporting_text: >-
Structural changes at the baseline were detected in 14 of 16 (87.5%) eyes on
WAFP and WAFAF and 13 of 16 (81.2%) eyes on SD-OCT.
- statement: >-
Functional full-field ERG changes were detected in 68.7% of npAIR eyes at
baseline.
supporting_text: >-
Functional changes were detected in 14 of 16 (87.5%) eyes on GVF, 15 of 16
(93.7%) eyes on MP, and 11 of 16 (68.7%) eyes on full-field electroretinogram
(ff-ERG).
- reference: PMID:41029312
title: >-
Autoimmune retinopathy in patients with myasthenia gravis: cases series and
literature review.
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
Main ocular manifestations were bilateral, subacute, painless vision loss with
diffuse pigmentary retinopathy, rod and cone ERG dysfunction.
supporting_text: >-
The main ocular manifestations of AIR were bilateral, subacute, painless
vision loss. The fundus examinations showed diffuse pigmentary retinopathy
and atrophy of retina. Electroretinography (ERG) showed dysfunction of rod
and cone cell.
- reference: PMID:36473045
title: >-
Ocular Paraneoplastic Syndromes: A Critical Review of Diffuse Uveal Melanocytic
Proliferation and Autoimmune Retinopathy.
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
The variety of local and systemic treatment options makes interpretation of
clinical effectiveness difficult in paraneoplastic retinopathies.
supporting_text: >-
The number of clinical variables that influence visual outcome in
paraneoplastic retinopathies combined with the variety of local and systemic
treatment options makes interpretation of clinical effectiveness difficult.
- statement: >-
The rarity of these disorders makes randomized clinical trials unlikely.
supporting_text: >-
The rarity of these disorders makes randomized clinical trials unlikely.
- reference: PMID:35571681
title: "Autoimmune Retinopathy, Testing, and Its Controversies."
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
AIRs characterized by progressive unexplained visual loss, visual field
contraction, photoreceptor and ERG dysfunction, and circulating anti-retinal
antibodies.
supporting_text: >-
AIRs are a group of inflammatory conditions affecting the retina
characterized by progressive unexplained visual loss, abnormalities and
contraction in visual fields, photoreceptor and electroretinographic
dysfunction, and the presence of circulating anti-retinal antibodies.
- reference: PMID:34562437
title: >-
Broad locations of antigenic regions for anti-TRPM1 autoantibodies in
paraneoplastic retinopathy with retinal ON bipolar cell dysfunction.
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
CARBD, including MAR, is caused by autoantibodies against molecules expressed
in ON bipolar cells, including TRPM1.
supporting_text: >-
Cancer-associated retinal ON bipolar cell dysfunction (CARBD), which includes
melanoma-associated retinopathy (MAR), has been reported to be caused by
autoantibodies against the molecules expressed in ON bipolar cells, including
TRPM1.
- statement: >-
Antigenic regions for anti-TRPM1 autoantibodies are spread across the
N-terminal intracellular, transmembrane-containing, and C-terminal
intracellular domains of TRPM1.
supporting_text: >-
The antigen regions were spread over the entire TRPM1 protein: five sera in
the N-terminal intracellular domain, six sera in the transmembrane-containing
region, and six sera in the C-terminal intracellular domain.
- reference: PMID:16444517
title: "Recoverin as a cancer-retina antigen."
found_in:
- Autoimmune_Retinopathy-deep-research-falcon.md
findings:
- statement: >-
Aberrant expression of recoverin in cancer cells and anti-recoverin autoantibodies
are essential for CAR, resulting in photoreceptor apoptosis.
supporting_text: >-
The aberrant expression of recoverin in cancer cells and the presence of
autoantibodies against recoverin are essential for the occurrence of
cancer-associated retinopathy, which finally results in the apoptosis of
photoreceptor cells.
- reference: PMID:38946992
title: >-
Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated
Retinopathy Patient.
found_in: []
findings:
- statement: >-
MAR patients develop vision deficits including reduced night vision, poor
contrast sensitivity, and photopsia; caused by TRPM1 autoantibodies blocking
ON-bipolar cell function.
supporting_text: >-
Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome associated
with cutaneous metastatic melanoma in which patients develop vision deficits
that include reduced night vision, poor contrast sensitivity, and photopsia.
MAR is caused by autoantibodies targeting TRPM1, an ion channel found in
melanocytes and retinal ON-bipolar cells (ON-BCs).
- reference: PMID:33796514
title: "Cancer-Associated Retinopathy due to Clear Cell Renal Carcinoma."
found_in: []
findings:
- statement: >-
A CAR patient presented with bilateral scotomas, progressive nyctalopia, and
reduced color vision.
supporting_text: >-
An 84-year-old female presented with bilateral scotomas and progressive
nyctalopia over 1 year. Best-corrected visual acuity was 20/50 in both eyes
with reduced color vision.
- reference: PMID:40986840
title: >-
A 10-year-old Girl with an 8-Month History of Progressive Photophobia and
Hemeralopia.
found_in: []
findings:
- statement: >-
A nonparaneoplastic AIR patient presented with decreased color vision and
improved with rituximab treatment.
supporting_text: >-
Upon detection of anti-retinal antibodies, treatment was initiated with
stabilization and improvement of visual acuity and ERG responses with
rituximab treatment.
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Autoimmune retinopathy (AIR) refers to a cluster of rare autoimmune disorders that lead to progressive retinal degeneration characterized by rapid and progressive deterioration of vision linked to the presence of circulating anti-retinal autoantibodies (ARAs) (kalogeropoulos2025diagnosisandtreatment pages 1-2). "AIR comprises a group of rare autoimmune disorders causing retinal degeneration, characterized by rapid vision deterioration linked to circulating anti-retinal autoantibodies (ARAs)" (kalogeropoulos2025diagnosisandtreatment pages 1-2). The disease accounts for less than 1% of all cases managed at tertiary referral centers (kalogeropoulos2025diagnosisandtreatment pages 2-4).
AIR can be categorized into paraneoplastic (pAIR) and non-paraneoplastic (npAIR) forms (kalogeropoulos2025diagnosisandtreatment pages 1-2). The paraneoplastic category comprises: - Cancer-associated retinopathy (CAR): Associated with non-melanoma malignancies - Melanoma-associated retinopathy (MAR): Specifically associated with melanoma
The non-paraneoplastic form (npAIR) occurs in the absence of malignancy and is diagnosed by ruling out other possible etiologies (kalogeropoulos2025diagnosisandtreatment pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 2-4).
Alternative names: Paraneoplastic retinopathy, autoimmune retinitis
Currently no OMIM, Orphanet, or MONDO IDs were identified in the available literature. The disease lacks standardized international diagnostic codes, which contributes to challenges in epidemiological tracking (kalogeropoulos2025diagnosisandtreatment pages 20-22).
The first case of CAR was reported in 1976 by Sawyer et al. in three females with bronchial carcinoma who developed vision loss due to photoreceptor degeneration (kalogeropoulos2025diagnosisandtreatment pages 2-4). In 1987, Thirkill et al. discovered a 23-kDa retinal antigen (later identified as recoverin) targeted by antibodies in CAR patients (kalogeropoulos2025diagnosisandtreatment pages 2-4). The term "paraneoplastic retinopathy" was introduced by Klingele et al. in 1984, and the first case of MAR was described by Gass in 1984 (kalogeropoulos2025diagnosisandtreatment pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 2-4). The first cases of AIR without underlying neoplasia (npAIR) were recorded in 1997 (kalogeropoulos2025diagnosisandtreatment pages 2-4).
Information is derived from disease-level resources including case series, retrospective studies, and comprehensive literature reviews published between 2020-2025 (kalogeropoulos2025diagnosisandtreatment pages 1-2, beuzit2025paraneoplasticocularsyndromes pages 1-2, chen2025autoimmuneretinopathyin pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 2-4).
Primary Mechanisms: 1. Autoimmune/Immunological: The core mechanism involves the production of antiretinal autoantibodies (ARAs) that target specific retinal proteins, leading to retinal cell death through various pathways including apoptosis and inflammation (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 4-5).
Paraneoplastic (for CAR/MAR): Malignant and benign cancers elicit an immune response where tumoral antigens exposed to antigen-presenting cells induce the production of ARAs against epitopes that cross-react with retinal proteins through molecular mimicry (kalogeropoulos2025diagnosisandtreatment pages 4-5).
Molecular Mimicry: Similarity between proteins present in pathogens and the retina can lead to autoantibody production. An example occurs in the glycolytic pathway, which plays crucial metabolic roles in both microbial and retinal cells (kalogeropoulos2025diagnosisandtreatment pages 4-5).
Retinal Injury-Induced: Various factors including trauma, inflammation, vascular disorders, and degenerative diseases may induce cellular stress in photoreceptors, leading to apoptosis and generation of metabolic debris that contributes to autoimmunization (kalogeropoulos2025diagnosisandtreatment pages 4-5).
Genetic Risk Factors: - HLA-DRB1-03 and HLA-DRB1-15 associations: A study of 24 npAIR patients found substantial correlation with these HLA alleles (kalogeropoulos2025diagnosisandtreatment pages 5-7) - No specific Mendelian inheritance pattern has been identified
Environmental and Clinical Risk Factors: - Malignancy (for pAIR): - Lung cancer: 16% of CAR/MAR cases - Breast cancer: 16% - Melanoma: 16% - Hematological malignancies: 15% - Gynecological cancers: 9% - Prostate cancer: 7% - Colon cancer: 6% (kalogeropoulos2025diagnosisandtreatment pages 2-4)
Autoimmune Disease History: 66.7% (16/24) of npAIR patients had a history of autoimmune disorder, most frequently hypothyroidism (kalogeropoulos2025diagnosisandtreatment pages 2-4)
Female Sex: Higher prevalence in women (62.5-79.2% of npAIR patients are female) (kalogeropoulos2025diagnosisandtreatment pages 2-4)
Age: Middle-aged to older adults most affected (mean age 47-62 years depending on subtype) (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 9-10)
No specific protective factors have been identified in the literature reviewed.
The development of pAIR appears to involve gene-environment interactions where tumor antigens (environmental trigger) in genetically susceptible individuals lead to cross-reactive autoantibody production through molecular mimicry (kalogeropoulos2025diagnosisandtreatment pages 4-5). The interaction between HLA risk alleles and environmental triggers (cancer, infections) may determine disease susceptibility, though this mechanism requires further study (kalogeropoulos2025diagnosisandtreatment pages 5-7).
| Characteristic | CAR | MAR | npAIR |
|---|---|---|---|
| Age at onset | Mean age for paraneoplastic AIR (CAR/MAR combined) is ~55 years, range 18–88; CAR patients tend to be older than npAIR patients (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 9-10) | Typically middle-aged to older adults, often 40–70 years (kalogeropoulos2025diagnosisandtreatment pages 9-10) | Younger than paraneoplastic AIR on average; reported mean 47–55.9 years, median 47 years, range 11–88 (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 9-10) |
| Sex predilection | Female predominance overall in AIR/paraneoplastic cohorts, though CAR can affect both sexes (kalogeropoulos2025diagnosisandtreatment pages 2-4) | Slight male predominance reported, consistent with melanoma demographics (kalogeropoulos2025diagnosisandtreatment pages 9-10) | Predominantly female; 62.5%–79.2% female in reported series (kalogeropoulos2025diagnosisandtreatment pages 2-4) |
| Associated conditions | Systemic malignancy, especially lung cancer, breast cancer, gynecologic malignancy, hematologic malignancy, and other solid tumors (kalogeropoulos2025diagnosisandtreatment pages 2-4, beuzit2025paraneoplasticocularsyndromes pages 1-2) | Cutaneous or metastatic melanoma; may signal immune response to metastasis (kalogeropoulos2025diagnosisandtreatment pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 10-13) | No malignancy; often associated with personal/family autoimmune history, especially thyroid disease/hypothyroidism and other autoimmune disorders (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 20-22) |
| Primary symptoms | Progressive, painless, bilateral or asymmetric vision loss; photosensitivity, glare, flickering/shimmering lights, central scotoma, night blindness, impaired dark adaptation, peripheral field defects (kalogeropoulos2025diagnosisandtreatment pages 9-10) | Night blindness, photopsia, visual field defects; central/paracentral scotomas common, VA often relatively preserved early (kalogeropoulos2025diagnosisandtreatment pages 9-10) | Gradual or subacute painless bilateral vision loss with photopsias and scotomas; may show visual field loss and color vision impairment (chen2025autoimmuneretinopathyin pages 3-4, kalogeropoulos2025diagnosisandtreatment pages 9-10) |
| Photoreceptor involvement | Often cone-predominant or mixed cone-rod dysfunction; simultaneous rod and cone involvement common, especially with anti-recoverin antibodies (kalogeropoulos2025diagnosisandtreatment pages 9-10) | Classically ON-bipolar cell dysfunction rather than primary photoreceptor loss, though broader retinal dysfunction may occur (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 9-10) | Variable cone, rod, or mixed photoreceptor dysfunction; progressive outer retinal degeneration is typical (chen2025autoimmuneretinopathyin pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 9-10) |
| Fundus findings | Often initially normal despite severe symptoms; later retinal arteriole attenuation, waxy optic disc pallor, RPE changes; occasional iritis/vitritis (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13) | Fundus may be normal or show optic disc pallor, vascular attenuation, RPE change, and vitreous cells/inflammation (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13) | Fundus may be normal early; can develop diffuse pigmentary retinopathy, retinal atrophy, RPE change, disc pallor, and hypo/hyper-autofluorescent abnormalities (chen2025autoimmuneretinopathyin pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 10-13) |
| ERG findings | Abnormal ERG is a core diagnostic feature; mixed cone/rod and isolated rod responses may be markedly attenuated (kalogeropoulos2025diagnosisandtreatment pages 10-13, kalogeropoulos2025diagnosisandtreatment pages 20-22) | Typically electronegative ERG/ON-bipolar dysfunction pattern; negative ERG is characteristic of MAR (kalogeropoulos2025diagnosisandtreatment pages 4-5) | Abnormal ERG required/supportive for diagnosis; rod and cone dysfunction common, often reduced responses on full-field ERG (chen2025autoimmuneretinopathyin pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 20-22) |
| Common antibodies | Anti-recoverin, anti-α-enolase, anti-CAII, anti-transducin; anti-recoverin is the classic CAR antibody (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 4-5) | Anti-TRPM1 is the best-characterized MAR antibody; anti-transducin also reported (kalogeropoulos2025diagnosisandtreatment pages 4-5) | Anti-recoverin, anti-α-enolase, anti-CAII, anti-arrestin, anti-IRBP, anti-TULP1, anti-TRPM1 and others; serology is heterogeneous (kalogeropoulos2025diagnosisandtreatment pages 4-5, chen2025autoimmuneretinopathyin pages 3-4) |
| Prognosis | Often poor visual prognosis; can progress to blindness over days to years; 49.1% worsened in a recent paraneoplastic ocular syndrome review, but early oncologic diagnosis (<6 months) improved outcomes (beuzit2025paraneoplasticocularsyndromes pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 10-13) | Variable; limited follow-up suggests ~half have unilateral or bilateral moderate-to-severe vision loss at last follow-up (kalogeropoulos2025diagnosisandtreatment pages 9-10) | Variable and heterogeneous; may stabilize or improve with immunosuppression, but chronic progressive loss and CME-associated worse outcomes are recognized (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 22-23) |
Table: This table compares the three principal autoimmune retinopathy subtypes across demographics, associated conditions, symptoms, retinal physiology, antibodies, and prognosis. It is useful for quickly distinguishing paraneoplastic from non-paraneoplastic disease patterns.
Common Symptoms: - Progressive bilateral vision loss: Painless, subacute to chronic (days to years) - Photopsia: Flickering, shimmering lights, or flashes - Scotomas: Central, paracentral, or ring scotomas - Night blindness (nyctalopia): Particularly in rod-predominant disease - Photosensitivity and glare - Impaired dark adaptation - Color vision defects - Peripheral visual field constriction (kalogeropoulos2025diagnosisandtreatment pages 1-2, chen2025autoimmuneretinopathyin pages 1-2, chen2025autoimmuneretinopathyin pages 3-4, kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13)
HPO Terms (Suggested): - HP:0000572: Visual loss - HP:0000505: Visual impairment - HP:0000529: Progressive visual loss - HP:0012372: Abnormal cone/rod electroretinogram - HP:0000662: Nyctalopia (night blindness) - HP:0000613: Photophobia - HP:0030453: Abnormal visual field - HP:0007994: Peripheral visual field loss - HP:0007973: Abnormal retinal morphology
Age of Onset: - CAR/MAR: Mean 55 years (range 18-88 years) (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 9-10) - npAIR: Younger, mean 47-55.9 years, median 47 years (range 11-88 years) (kalogeropoulos2025diagnosisandtreatment pages 2-4)
Symptom Severity: Variable, ranging from mild visual disturbance to complete blindness. CAR has particularly poor prognosis with 49.1% experiencing worsening vision (beuzit2025paraneoplasticocularsyndromes pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 10-13).
Symptom Progression: - Progressive: Most cases show relentless progression without treatment - Time Course: Can progress from days to years - Pattern: Bilateral but often asymmetric initially; may involve both rods and cones or be photoreceptor-subtype selective
Frequency: - Bilateral involvement: >90% of cases eventually bilateral (beuzit2025paraneoplasticocularsyndromes pages 1-2) - Mixed rod-cone dysfunction: Common, especially with anti-recoverin antibodies (kalogeropoulos2025diagnosisandtreatment pages 9-10) - Cystoid macular edema (CME): Frequent complication, present in significant proportion of npAIR patients and associated with worse outcomes (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13)
Visual disability from AIR significantly impacts daily functioning and quality of life. CME is a biomarker of more severe and more progressive disease and is associated with rapid ellipsoid zone loss, worse visual acuity, and poorer visual outcomes (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13). The disease causes preventable blindness and substantial psychosocial burden due to progressive, often irreversible vision loss affecting working-age adults (kalogeropoulos2025diagnosisandtreatment pages 2-4).
AIR is not caused by mutations in specific genes but rather by autoantibodies targeting retinal proteins. The disease involves humoral autoimmunity rather than traditional Mendelian genetic causation.
| Antibody name | Molecular weight (kDa) | Target antigen | Cell types affected | Mechanism of action / pathogenic effect | Association (CAR/MAR/npAIR) |
|---|---|---|---|---|---|
| Anti-recoverin | 23 | Recoverin, a photoreceptor calcium-binding protein | Photoreceptors (rods and cones) | Antibody binding is associated with intracellular calcium dysregulation and caspase-mediated apoptosis, causing photoreceptor degeneration and vision loss; among the best-studied pathogenic AIR antibodies (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 5-7) | CAR, npAIR; also reported broadly across AIR spectrum (kalogeropoulos2025diagnosisandtreatment pages 4-5) |
| Anti-α-enolase | 46 | α-Enolase, a glycolytic enzyme | Ganglion cells, Müller cells, rods, cones | Inhibits enolase catalytic function, leading to ATP depletion, increased intracellular calcium, and apoptotic retinal cell death (kalogeropoulos2025diagnosisandtreatment pages 4-5) | CAR, MAR, npAIR (kalogeropoulos2025diagnosisandtreatment pages 4-5) |
| Anti-rod transducin | 38 | Rod transducin (phototransduction G-protein) | Rod photoreceptors | Disrupts phototransduction signaling; abnormal antigen expression in cancer cells may trigger cross-reactive autoimmunity, with downstream calcium imbalance and apoptosis proposed (kalogeropoulos2025diagnosisandtreatment pages 4-5) | CAR, MAR, npAIR (kalogeropoulos2025diagnosisandtreatment pages 4-5) |
| Anti-arrestin (S-antigen) | 48 | Arrestin / S-antigen | Retinal cells, especially photoreceptor-associated pathways | Interferes with phototransduction regulation; recognized as a recurrent npAIR antigen, but direct pathogenic evidence is less developed than for recoverin/enolase (kalogeropoulos2025diagnosisandtreatment pages 4-5) | Primarily npAIR (kalogeropoulos2025diagnosisandtreatment pages 4-5) |
| Anti-carbonic anhydrase II (CA-II) | 30 | Carbonic anhydrase II | Retinal cells | Impairs CA-II catalytic activity, decreases intracellular pH, increases intracellular calcium, and reduces retinal cell viability, contributing to retinal degeneration (kalogeropoulos2025diagnosisandtreatment pages 4-5) | CAR and AIR without cancer / npAIR (kalogeropoulos2025diagnosisandtreatment pages 4-5) |
| Anti-IRBP | 141 | Interphotoreceptor retinoid-binding protein (IRBP) | Photoreceptor-retinoid interface / interphotoreceptor matrix | Disrupts retinoid transport and photoreceptor homeostasis; listed as a recurrent npAIR target, with pathogenic relevance suggested but less directly proven than recoverin/enolase (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 7-8) | Primarily npAIR (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 7-8) |
| Anti-TRPM1 | 182 | TRPM1 cation channel | Retinal ON-bipolar cells | In animal transfer experiments, anti-TRPM1 antibodies altered ERG responses and induced acute ON-bipolar cell death, explaining electronegative ERG/ON-bipolar dysfunction typical of MAR-like disease (kalogeropoulos2025diagnosisandtreatment pages 4-5) | MAR; also paraneoplastic retinopathy more broadly (kalogeropoulos2025diagnosisandtreatment pages 4-5) |
| Anti-TULP1 | 64 | Tubby-like protein 1 (TULP1) | Photoreceptors | Associated with photoreceptor dysfunction/degeneration; reported as a candidate AIR autoantigen, but pathogenic mechanism remains less well established than canonical antibodies (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 7-8) | Reported in npAIR / broader AIR spectrum (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 7-8) |
Table: This table summarizes the principal antiretinal autoantibodies implicated in autoimmune retinopathy, including their molecular targets, affected retinal cell types, proposed pathogenic mechanisms, and disease associations across CAR, MAR, and non-paraneoplastic AIR.
Key autoantibodies include:
Anti-recoverin (23 kDa): Targets photoreceptor calcium-binding protein; causes calcium dysregulation, caspase-mediated apoptosis, and photoreceptor degeneration (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 5-7)
Anti-α-enolase (46 kDa): Targets glycolytic enzyme; inhibits catalytic function leading to ATP depletion, increased intracellular calcium, and apoptosis (kalogeropoulos2025diagnosisandtreatment pages 4-5)
Anti-TRPM1 (182 kDa): Targets cation channel in ON-bipolar cells; animal studies show it alters ERG and induces acute bipolar cell death, characteristic of MAR (kalogeropoulos2025diagnosisandtreatment pages 4-5)
Anti-carbonic anhydrase II (30 kDa): Impairs catalytic activity, decreases intracellular pH, increases calcium, reduces cell viability (kalogeropoulos2025diagnosisandtreatment pages 4-5)
Anti-rod transducin (38 kDa): Disrupts phototransduction; abnormal expression in cancer triggers cross-reactivity (kalogeropoulos2025diagnosisandtreatment pages 4-5)
Anti-arrestin/S-antigen (48 kDa): Interferes with phototransduction regulation; common in npAIR (kalogeropoulos2025diagnosisandtreatment pages 4-5)
Anti-IRBP (141 kDa): Disrupts retinoid transport and photoreceptor homeostasis (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 7-8)
Anti-TULP1 (64 kDa): Associated with photoreceptor dysfunction (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 7-8)
HLA-DRB1-03 and HLA-DRB1-15 appear to modify disease susceptibility in npAIR, with substantial correlation noted in affected patients (kalogeropoulos2025diagnosisandtreatment pages 5-7).
Mechanisms of Retinal Cell Death: - Calcium Dysregulation: Anti-recoverin and anti-enolase antibodies increase intracellular calcium levels, triggering apoptosis (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 5-7) - ATP Depletion: Anti-enolase inhibits glycolysis, depleting cellular energy (kalogeropoulos2025diagnosisandtreatment pages 4-5) - Caspase Activation: Multiple antibodies trigger caspase-mediated apoptotic pathways (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 5-7) - pH Disruption: Anti-CAII causes intracellular acidification (kalogeropoulos2025diagnosisandtreatment pages 4-5) - Phototransduction Disruption: Multiple antibodies interfere with visual signal transduction (kalogeropoulos2025diagnosisandtreatment pages 4-5)
Epigenetic Information: No specific epigenetic changes have been characterized in AIR.
Chromosomal Abnormalities: Not applicable; AIR is not caused by chromosomal abnormalities.
Malignancy as Environmental Trigger: The presence of cancer acts as the primary environmental trigger in pAIR. Tumor cells expressing retinal-like antigens initiate cross-reactive immune responses (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 4-5).
Infectious Agents: Molecular mimicry between retinal antigens and proteins present in pathogens (bacteria or viruses) may trigger npAIR through cross-reactive antibody production (kalogeropoulos2025diagnosisandtreatment pages 4-5).
No specific lifestyle factors (smoking, diet, exercise, alcohol) have been definitively linked to AIR risk.
"Although the presence of ARAs in the patients' serum is confirmed, their precise role remains uncertain. It is likely that these ARAs are produced due to an overly aggressive immune response to antigens in the retina" (kalogeropoulos2025diagnosisandtreatment pages 2-4).
Apoptotic Pathways: Multiple ARAs trigger apoptosis through: - Caspase-3 activation (kalogeropoulos2025diagnosisandtreatment pages 4-5, kalogeropoulos2025diagnosisandtreatment pages 5-7) - Cytochrome c release (kalogeropoulos2025diagnosisandtreatment pages 5-7) - Balance shift toward pro-apoptotic proteins (kalogeropoulos2025diagnosisandtreatment pages 5-7)
Calcium Signaling: Disrupted calcium homeostasis is a central mechanism. "Exposure to these antibodies increased intracellular calcium levels, which could be suppressed by a calcium channel blocker called nifedipine" (kalogeropoulos2025diagnosisandtreatment pages 5-7), suggesting calcium channel involvement in pathogenesis.
Metabolic Dysfunction: Anti-enolase "inhibited enolase's catalytic function, leading to ATP depletion, increased intracellular calcium levels, and apoptotic cell death" (kalogeropoulos2025diagnosisandtreatment pages 4-5).
Inflammatory Pathways: Blood-retinal barrier disruption, upregulation of MCP-1 (CCL2) chemokine, and attraction of macrophages/microglia contribute to photoreceptor damage (kalogeropoulos2025diagnosisandtreatment pages 5-7).
GO Terms (Suggested): - GO:0006915: apoptotic process - GO:0006954: inflammatory response - GO:0006816: calcium ion transport - GO:0006096: glycolytic process - GO:0007601: visual perception - GO:0009416: response to light stimulus - GO:0007602: phototransduction
ARAs cause protein dysfunction through: - Loss of Function: Enzyme inhibition (enolase, CAII) - Dominant Negative Effect: Antibody binding preventing normal protein function - Conformational Changes: Antibody-induced structural alterations
Autoimmune Mechanism: AIR involves breakdown of ocular immune privilege with generation of pathogenic autoantibodies against retinal self-antigens (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 4-5). The thymus-retina connection is important: "The retina contains numerous proteins expressed also in the thymus, as well as other secondary lymphoid tissues. In the thymus, the process of negative selection plays a crucial role in establishing self-tolerance" (kalogeropoulos2025diagnosisandtreatment pages 2-4).
Cell Types Involved (CL Terms Suggested): - CL:0000573: retinal cone cell - CL:0000604: retinal rod cell - CL:0000748: retinal bipolar neuron - CL:0000129: microglial cell - CL:0000235: macrophage - CL:0000236: B cell
Primary Organ: Eye - specifically the retina (UBERON:0000966)
Body System: - Sensory system (visual system) - UBERON:0002104 (visual system)
Tissues Affected: - Neural retina (UBERON:0000966) - Retinal pigment epithelium (UBERON:0001782) - Photoreceptor layer (UBERON:0001791)
Cell Populations Targeted: - Photoreceptors (rods: CL:0000604, cones: CL:0000573) - Retinal bipolar neurons (CL:0000748) - especially in MAR - Retinal ganglion cells (CL:0000740) - Müller cells (CL:0000636)
Cellular Compartments (GO Cellular Component Terms): - GO:0001750: photoreceptor outer segment - GO:0042995: cell projection - GO:0005886: plasma membrane - GO:0005739: mitochondrion (metabolic dysfunction site) - GO:0005737: cytoplasm (site of glycolytic enzyme disruption)
Anatomical Sites: - Posterior pole (macula) - Peripheral retina - Parafoveal and perifoveal regions
Lateralization: Bilateral but often asymmetric initially; eventually bilateral in >90% (beuzit2025paraneoplasticocularsyndromes pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 9-10)
Typical Age of Onset: - pAIR (CAR/MAR): Mean 55 years (range 18-88) - npAIR: Mean 47-55.9 years (range 11-88) - Predominantly adult-onset (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 9-10)
Onset Pattern: Subacute to chronic; painless progression over days to years (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13)
Disease Stages: Not formally staged, but progression includes: - Early: Symptoms with normal-appearing fundus - Intermediate: Detectable retinal changes on imaging (FAF, OCT, ERG abnormalities) - Advanced: Visible fundus changes, severe vision loss, widespread retinal atrophy
Progression Rate: Variable; can be rapid (days to weeks) or slow (months to years). Latency between cancer diagnosis and retinopathy onset: weeks to months for lung cancers and lymphomas; years for breast and prostate cancers (kalogeropoulos2025diagnosisandtreatment pages 2-4).
Disease Course Pattern: - Progressive in most untreated cases - Relapsing-remitting pattern not typical - Chronic course leading to irreversible retinal damage
Disease Duration: Chronic, lifelong once established
Remission: Spontaneous remission is not characteristic. Treatment-induced stabilization or improvement may occur with immunosuppression (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 22-23).
Critical Periods: Early diagnosis is critical as retinal damage becomes irreversible. In CAR, early oncologic diagnosis (within 6 months after symptom onset) was significantly associated with favorable visual outcome (p = 0.03) (beuzit2025paraneoplasticocularsyndromes pages 1-2).
Prevalence: Extremely rare; accounts for less than 1% of cases at tertiary referral centers (kalogeropoulos2025diagnosisandtreatment pages 2-4). No population-based prevalence data available.
Incidence: Not reported in available literature.
Inheritance Pattern: Not a Mendelian inherited disorder. AIR is an acquired autoimmune condition. No evidence of familial clustering or traditional inheritance patterns.
HLA Associations: Substantial correlation with HLA-DRB1-03 and HLA-DRB1-15 in npAIR (kalogeropoulos2025diagnosisandtreatment pages 5-7).
Affected Populations: - Female predominance (62.5-79.2% in npAIR; female predominance also in pAIR) (kalogeropoulos2025diagnosisandtreatment pages 2-4) - Middle-aged to older adults most affected
Cancer Associations in pAIR: - Lung: 16% - Breast: 16% - Melanoma: 16% - Hematological: 15% - Gynecological: 9% - Prostate: 7% - Colon: 6% (kalogeropoulos2025diagnosisandtreatment pages 2-4)
Geographic Distribution: No specific geographic clustering reported. Disease described worldwide in literature from multiple countries (kalogeropoulos2025diagnosisandtreatment pages 1-2, beuzit2025paraneoplasticocularsyndromes pages 1-2, chen2025autoimmuneretinopathyin pages 1-2).
Sex Ratio: Predominantly female (approximately 2-3:1 female:male ratio in npAIR) (kalogeropoulos2025diagnosisandtreatment pages 2-4).
Age Distribution: Peak incidence in middle to older adulthood (40-70 years) (kalogeropoulos2025diagnosisandtreatment pages 2-4, kalogeropoulos2025diagnosisandtreatment pages 9-10).
Laboratory Tests: - Serum antiretinal antibody (ARA) testing: Essential but not always positive. Methods include immunohistochemistry (IHC), Western blotting (WB), and ELISA. "It is recommended to employ two techniques simultaneously to enhance both sensitivity and specificity" (kalogeropoulos2025diagnosisandtreatment pages 20-22). - Less than half (47.1%, 111/193) of clinically diagnosed AIR patients tested positive for ARAs (kalogeropoulos2025diagnosisandtreatment pages 5-7)
Biomarkers: - Circulating ARAs (recoverin, enolase, TRPM1, etc.) - CME on OCT as biomarker of disease severity and progression (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13)
Imaging Studies: - Optical Coherence Tomography (OCT): Shows outer retinal layer atrophy, ellipsoid zone disruption, CME, retinal thinning (kalogeropoulos2025diagnosisandtreatment pages 10-13) - Fundus Autofluorescence (FAF): Granular hyperautofluorescence in posterior pole, macular/peripapillary regions; large areas of peripheral hyperautofluorescence creating demarcation lines (kalogeropoulos2025diagnosisandtreatment pages 10-13) - Fluorescein Angiography (FA): May show retinal vascular leakage - Fundus Photography: Documents pigmentary changes, vascular attenuation, disc pallor
Functional Tests: - Electroretinography (ERG): Abnormal ERG is a core diagnostic feature. Shows: - Reduced or absent mixed cone-rod responses - Attenuated isolated rod responses - Electronegative ERG pattern in MAR (characteristic ON-bipolar dysfunction) (kalogeropoulos2025diagnosisandtreatment pages 10-13, kalogeropoulos2025diagnosisandtreatment pages 20-22) - Visual Field Testing: Demonstrates central scotomas, ring scotomas, peripheral field loss (kalogeropoulos2025diagnosisandtreatment pages 10-13) - Color Vision Testing: Impaired color discrimination
Pathology Findings: Histopathology rarely performed; when available, shows photoreceptor loss, RPE atrophy, inflammatory infiltrates.
Not applicable for diagnosis. Genetic testing may be used to rule out inherited retinal dystrophies in the differential diagnosis (kalogeropoulos2025diagnosisandtreatment pages 20-22).
Differential Diagnosis Genetic Testing: - Screening for retinitis pigmentosa genes - Cone-rod dystrophy gene panels - Necessary to distinguish npAIR from inherited retinal diseases (IRDs) (kalogeropoulos2025diagnosisandtreatment pages 20-22)
Diagnostic Criteria (2016 consensus, though no international consensus exists): - Absence of other identifiable causes of visual function abnormalities - Abnormal ERG results - Presence of serum ARAs - Absence of significant intraocular inflammation (kalogeropoulos2025diagnosisandtreatment pages 10-13)
Supportive Criteria: - Personal/family history of autoimmune disease - Signs/symptoms of photoreceptor dysfunction - Rapid onset of vision changes (kalogeropoulos2025diagnosisandtreatment pages 10-13)
Differential Diagnosis: - White Dot Syndrome spectrum (AZOOR, MEWDS) - Inherited retinal dystrophies (retinitis pigmentosa, cone-rod dystrophy) - Infectious/non-infectious uveitis - Paraneoplastic conditions affecting RPE (BDUMP) - Drug toxicity (hydroxychloroquine) - Pseudo-retinitis pigmentosa (syphilis) (kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 10-13)
Cancer Screening in pAIR: Comprehensive oncological workup essential. Imaging (CT, PET-CT), tumor markers, and targeted screening based on age/sex (beuzit2025paraneoplasticocularsyndromes pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 10-13).
At-Risk Population Monitoring: Patients with known autoimmune diseases should be monitored for visual symptoms (kalogeropoulos2025diagnosisandtreatment pages 2-4).
AIR itself is not directly life-threatening, but associated malignancies in pAIR significantly impact survival. The visual prognosis is generally poor to guarded.
Visual Outcomes: - CAR: Poor prognosis; 49.1% of patients experienced worsening vision in systematic review (beuzit2025paraneoplasticocularsyndromes pages 1-2) - Early oncologic diagnosis (<6 months from symptom onset) significantly associated with favorable visual outcome in CAR (p = 0.03) (beuzit2025paraneoplasticocularsyndromes pages 1-2) - MAR: Variable; approximately half had moderate to severe vision loss at last follow-up (kalogeropoulos2025diagnosisandtreatment pages 9-10) - npAIR: Variable; may stabilize with treatment but CME predicts worse outcomes (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13)
Disability: Progressive vision loss leading to legal blindness; significant impact on activities of daily living, employment, and quality of life.
Quality of Life: "CME is a biomarker of more severe and more progressive disease in npAIR and is associated with visual disability and impact productivity and quality of life" (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13).
Complications: - Cystoid macular edema (CME) - persistent despite treatment in some cases - Progressive ellipsoid zone loss - Retinal atrophy - Complete vision loss/blindness - Vitreous inflammation (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13)
Recovery Potential: Generally poor without treatment. Immunosuppression may stabilize or improve some cases, but irreversible photoreceptor loss limits recovery potential (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 22-23).
Prognostic Factors: - Time to cancer diagnosis (earlier better in CAR) (beuzit2025paraneoplasticocularsyndromes pages 1-2) - Presence of CME (worse prognosis) (kalogeropoulos2025diagnosisandtreatment pages 9-10, kalogeropoulos2025diagnosisandtreatment pages 10-13) - Shorter ellipsoid zone length (worse prognosis) - Specific antibody profile (mixed evidence) - Age (older may be worse) - Disease duration before treatment initiation
Prognostic Biomarkers: - CME on OCT - Ellipsoid zone length on OCT - ERG amplitude decline - Persistent/rising ARA titers
| Treatment category | Specific agents/approaches | Mechanism of action | Evidence level / response rates | Key references / notes |
|---|---|---|---|---|
| Corticosteroids (systemic) | Oral prednisone 60–80 mg/day; intravenous methylprednisolone induction | Broad anti-inflammatory and immunosuppressive effects; suppress autoimmune retinal injury | Evidence mainly from retrospective series and case reports; no standardized regimen; IV methylprednisolone reported to have better outcomes than oral prednisone in some reports (kalogeropoulos2025diagnosisandtreatment pages 22-23) | Common first-line therapy after excluding/treating underlying malignancy or systemic disease; early treatment considered important to limit irreversible retinal damage; no randomized controlled trials (kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23) |
| Corticosteroids (local) | Intravitreal triamcinolone; sub-Tenon triamcinolone; intravitreal sustained-release fluocinolone acetonide implant; topical/depot steroids | Local suppression of ocular inflammation with reduced systemic exposure | Brief intravitreal/sub-Tenon steroid trial has been proposed diagnostically/therapeutically; case reports describe restoration of retinal anatomy and vision improvement in CAR and benefit in MAR with fluocinolone implant; evidence limited to case reports/series (kalogeropoulos2025diagnosisandtreatment pages 22-23) | Suggested by some authors before prolonged systemic steroids to verify steroid responsiveness; used for CME and local disease control; protocol not standardized (kalogeropoulos2025diagnosisandtreatment pages 22-23) |
| Immunomodulators / steroid-sparing agents | Azathioprine, cyclosporine, mycophenolate mofetil, infliximab, methotrexate | Reduce adaptive immune activation and autoantibody-associated inflammation; steroid-sparing maintenance therapy | Retrospective triple-therapy series (cyclosporine + azathioprine + prednisone) in 30 patients reported overall response in 70%; among npAIR, 54% without CME and 73% with CME responded, but study limitations were substantial (kalogeropoulos2025diagnosisandtreatment pages 22-23) | Frequently used when corticosteroids are insufficient or not tolerated; evidence is heterogeneous and vulnerable to publication bias; successful methotrexate use is not well documented in npAIR (kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23) |
| Biologic agents | Rituximab; tocilizumab; sarilumab; alemtuzumab; ipilimumab | Rituximab depletes CD20+ B cells and pro-inflammatory CD3+CD20+ T cells; IL-6 blockade (tocilizumab/sarilumab) may reduce refractory CME/inflammation; ipilimumab augments anti-tumor immunity in melanoma-associated disease | Rituximab has the strongest biologic signal in AIR from retrospective series and case reports; one 16-patient series reported stable or improved visual outcomes in 77% of eyes with rituximab-based combinations; anti-IL-6 therapies reported complete resolution of refractory CME in isolated case reports (kalogeropoulos2025diagnosisandtreatment pages 22-23) | Biologics are generally used for refractory disease; evidence remains low-level and non-comparative; recent reviews emphasize lack of prospective trials and no standard treatment protocol (kalogeropoulos2025diagnosisandtreatment pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23) |
| IVIG | Intravenous immunoglobulin | Immunomodulation via Fc-mediated immune regulation, neutralization of pathogenic antibodies, and altered B/T-cell signaling | Evidence limited to case reports/small series; sometimes used in combination with steroids or other immunosuppressants; no robust response-rate estimate available (kalogeropoulos2025diagnosisandtreatment pages 22-23) | Considered an option in refractory AIR, especially when humoral autoimmunity is suspected; included among available therapies in recent review tables (kalogeropoulos2025diagnosisandtreatment pages 22-23) |
| Plasmapheresis / plasma exchange | Therapeutic plasma exchange, often combined with systemic immunosuppression | Removes circulating antiretinal autoantibodies and immune mediators | Evidence limited to case reports and small series; no standardized schedule or comparative efficacy data available (kalogeropoulos2025diagnosisandtreatment pages 22-23) | Mechanistically attractive for antibody-mediated disease, but current support is anecdotal; should be interpreted cautiously due to absence of controlled trials (kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23) |
| Tumor-directed therapies (paraneoplastic AIR) | Surgical cytoreduction, chemotherapy, radiotherapy; treatment of underlying malignancy before ocular immunosuppression | Reduces tumor antigen burden that may drive molecular mimicry and autoantibody production | Evidence indirect but clinically important; early oncologic diagnosis in CAR was associated with better visual outcomes in a recent paraneoplastic review; treatment of malignancy is foundational in pAIR (beuzit2025paraneoplasticocularsyndromes pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 22-23) | Recommended first in pAIR/CAR/MAR before or alongside ocular immunosuppression; MAR may indicate immune response to melanoma metastasis, and immunosuppression can theoretically worsen tumor control (beuzit2025paraneoplasticocularsyndromes pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 10-13, kalogeropoulos2025diagnosisandtreatment pages 22-23) |
| Overall treatment strategy / evidence gap | Multidisciplinary individualized care; combine oncology, ophthalmology, rheumatology/immunology; monitor ERG, OCT, FAF, visual fields | Tailors therapy to subtype (CAR, MAR, npAIR), systemic disease, and structural/functional progression | No international standard treatment protocol; evidence base is dominated by retrospective series and case reports; prospective randomized placebo-controlled trials are explicitly needed (kalogeropoulos2025diagnosisandtreatment pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23) | Current management is empirical; early diagnosis is repeatedly emphasized because retinal damage may become irreversible and pAIR can precede cancer detection (kalogeropoulos2025diagnosisandtreatment pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23) |
Table: This table summarizes the main currently reported treatment approaches for autoimmune retinopathy, their rationale, and the level of supporting evidence. It is useful because AIR management remains non-standardized and is based largely on retrospective series and case reports rather than prospective trials.
Corticosteroids: - Systemic: Prednisone 60-80 mg/day orally; IV methylprednisolone for induction (kalogeropoulos2025diagnosisandtreatment pages 22-23) - Local: Intravitreal triamcinolone (40-80 mg), sub-Tenon triamcinolone, sustained-release fluocinolone implant (kalogeropoulos2025diagnosisandtreatment pages 22-23) - Mechanism: Broad immunosuppression and anti-inflammatory effects - Evidence: Case series and retrospective studies; no RCTs (kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23)
Immunomodulators: - Azathioprine, cyclosporine, mycophenolate mofetil, methotrexate - Mechanism: Steroid-sparing agents; reduce adaptive immune activation - Evidence: Retrospective triple-therapy series (cyclosporine + azathioprine + prednisone) showed 70% overall response (kalogeropoulos2025diagnosisandtreatment pages 22-23) - MAXO terms: MAXO:0000882 (immunosuppressive therapy)
Biologic Agents: - Rituximab: Most extensively studied biologic; CD20+ B-cell depletion - Evidence: Multiple case series; 83.5% positive response in uveitis review; 77% stable/improved visual outcomes in AIR series (kalogeropoulos2025diagnosisandtreatment pages 22-23) - MAXO: MAXO:0001298 (rituximab therapy)
Evidence: Case reports showing complete resolution of refractory CME (kalogeropoulos2025diagnosisandtreatment pages 22-23)
Ipilimumab: For melanoma-associated MAR refractory to other treatments (kalogeropoulos2025diagnosisandtreatment pages 22-23)
Immunotherapies: IVIG mechanism includes Fc-mediated immune regulation and antibody neutralization; evidence limited to case reports (kalogeropoulos2025diagnosisandtreatment pages 22-23).
Tumor-Directed Surgery: Essential first-line in pAIR; cytoreduction, resection of primary malignancy (beuzit2025paraneoplasticocularsyndromes pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 22-23).
Response Rates: - Corticosteroids: Variable responses; no standardized efficacy data - Triple immunosuppression: 70% overall response (kalogeropoulos2025diagnosisandtreatment pages 22-23) - Rituximab: 83.5% positive response in non-infectious uveitis; 77% in AIR series (kalogeropoulos2025diagnosisandtreatment pages 22-23)
Adverse Events: - Corticosteroids: Systemic side effects (osteoporosis, weight gain, hyperglycemia, infection) - Rituximab: Infusion reactions most common (31.4% of adverse events); well-tolerated overall (kalogeropoulos2025diagnosisandtreatment pages 22-23) - Immunosuppressants: Infection risk, hepatotoxicity, bone marrow suppression
No Standard Protocol: "Currently, there is no standard treatment protocol for AIRs" (kalogeropoulos2025diagnosisandtreatment pages 20-22). Management is individualized based on: - Subtype (CAR, MAR, npAIR) - Presence of underlying malignancy - Disease severity and progression - Response to initial therapy
Typical Approach: 1. In pAIR: Address malignancy first (surgery, chemotherapy, radiotherapy) 2. Initiate corticosteroids (systemic ± local) 3. Add steroid-sparing immunomodulators if needed 4. Consider biologics (especially rituximab) for refractory disease 5. Multidisciplinary care (ophthalmology, oncology, rheumatology) (kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23)
Need for RCTs: "A prospective randomized placebo-controlled clinical trial could provide important insights on this topic" (kalogeropoulos2025diagnosisandtreatment pages 22-23).
Primary Prevention: No specific primary prevention strategies exist as AIR is an acquired autoimmune condition with unclear triggering factors.
Secondary Prevention: - Cancer Screening in pAIR: Early detection of malignancy improves visual outcomes. "Early oncologic diagnosis (within 6 months after symptom onset) was significantly associated with a favorable visual outcome (p = 0.03)" in CAR (beuzit2025paraneoplasticocularsyndromes pages 1-2) - Monitoring High-Risk Populations: Patients with known autoimmune diseases should be monitored for visual symptoms (kalogeropoulos2025diagnosisandtreatment pages 2-4)
Tertiary Prevention: - Early immunosuppressive therapy to prevent further retinal damage - Regular monitoring (ERG, OCT, visual fields) to detect progression - Management of CME to prevent further vision loss
Cancer Screening: Comprehensive oncological workup in all suspected pAIR cases, including: - Imaging (CT chest/abdomen/pelvis, PET-CT) - Tumor markers - Dermatologic examination for melanoma - Age/sex-appropriate cancer screening (beuzit2025paraneoplasticocularsyndromes pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 10-13)
Genetic Screening: Not applicable; AIR is not Mendelian inherited.
Risk Stratification: Patients with autoimmune disease history should be counseled about visual symptoms warranting ophthalmologic evaluation (kalogeropoulos2025diagnosisandtreatment pages 2-4).
Genetic Counseling: Not required; AIR is not inherited.
Patient Education: Importance of reporting visual symptoms; compliance with immunosuppression; cancer surveillance in pAIR.
No specific public health interventions applicable to this rare condition.
No preventive medications or procedures recommended for at-risk individuals.
No naturally occurring autoimmune retinopathy has been well-documented in non-human species in the reviewed literature.
Not applicable due to lack of natural animal disease models.
Experimental Autoimmune Uveitis (EAU) Models: - Mammalian Models: Mice, rats, rabbits - Induction Methods: Immunization with retinal antigens (recoverin, IRBP, retinal S-antigen)
Specific Models:
Metabolomic/lipidomic changes: High lactate, low ascorbic acid, increased PGE2, TXB2, 11-HETE, Lyso-PAF (kalogeropoulos2025diagnosisandtreatment pages 20-22)
IRBP-Induced EAU in Mice:
Used to test therapeutic interventions (kalogeropoulos2025diagnosisandtreatment pages 20-22)
ROS-Deficient (Ncf1−/−) Mice:
Phenotype Recapitulation: - Retinal inflammation - Photoreceptor dysfunction (ERG abnormalities) - Immune cell infiltration - Cytokine/chemokine elevation - Retinal structural damage
Model Limitations: - Does not fully replicate human AIR heterogeneity - Antibody-mediated mechanisms less studied than T-cell mechanisms in EAU - Acute/subacute models may not reflect chronic human disease course
Example: "Application of mitochondria-targeted antioxidant therapy impeded EAU progression by maintaining local antioxidant activity and suppressing TNF-α, IL-6 and PGE2 signaling" (kalogeropoulos2025diagnosisandtreatment pages 20-22).
Model organism databases: MGI (Mouse Genome Informatics), RGD (Rat Genome Database) for accessing EAU models.
Autoimmune retinopathy remains an enigmatic and challenging condition. Despite decades of research, several critical gaps persist:
Diagnostic Standardization: "There is currently no international consensus on diagnostic criteria or treatment protocols" (kalogeropoulos2025diagnosisandtreatment pages 1-2, kalogeropoulos2025diagnosisandtreatment pages 20-22)
Pathogenic Role of Antibodies: "It is still unclear whether the presence of antibodies serves as a causative factor or arises as a consequential outcome" (kalogeropoulos2025diagnosisandtreatment pages 1-2)
Treatment Evidence: Evidence base dominated by retrospective case series; "prospective randomized placebo-controlled clinical trials are explicitly needed" (kalogeropoulos2025diagnosisandtreatment pages 20-22, kalogeropoulos2025diagnosisandtreatment pages 22-23)
Epidemiology: No population-based prevalence/incidence data available
Predictive Biomarkers: Limited validated biomarkers for prognosis and treatment response
Future research should focus on prospective clinical trials, standardized diagnostic criteria, identification of pathogenic versus bystander antibodies, and development of targeted immunotherapies based on mechanistic understanding of antibody-mediated retinal damage.
References
(kalogeropoulos2025diagnosisandtreatment pages 1-2): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.
(kalogeropoulos2025diagnosisandtreatment pages 2-4): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.
(kalogeropoulos2025diagnosisandtreatment pages 20-22): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.
(beuzit2025paraneoplasticocularsyndromes pages 1-2): Solweig Beuzit, Aude Méal, Mathieu Delplanque, Jean-Christophe Ianotto, Béatrice Cochener-Lamard, Claire de Moreuil, and Bénédicte Rouvière. Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010–2023). Journal of Ophthalmic Inflammation and Infection, Sep 2025. URL: https://doi.org/10.1186/s12348-025-00534-1, doi:10.1186/s12348-025-00534-1. This article has 3 citations and is from a peer-reviewed journal.
(chen2025autoimmuneretinopathyin pages 1-2): Yiqiao Chen, Yexin Zhang, Jiaojiao Luo, Miaomiao Liu, Min Lin, Wenhua Zhu, Wenjun Xiong, Peiquan Zhao, Jianying Xi, and P. Fei. Autoimmune retinopathy in patients with myasthenia gravis: cases series and literature review. BMC Ophthalmology, Sep 2025. URL: https://doi.org/10.1186/s12886-025-04357-5, doi:10.1186/s12886-025-04357-5. This article has 0 citations and is from a peer-reviewed journal.
(kalogeropoulos2025diagnosisandtreatment pages 4-5): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.
(kalogeropoulos2025diagnosisandtreatment pages 5-7): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.
(kalogeropoulos2025diagnosisandtreatment pages 9-10): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.
(kalogeropoulos2025diagnosisandtreatment pages 10-13): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.
(chen2025autoimmuneretinopathyin pages 3-4): Yiqiao Chen, Yexin Zhang, Jiaojiao Luo, Miaomiao Liu, Min Lin, Wenhua Zhu, Wenjun Xiong, Peiquan Zhao, Jianying Xi, and P. Fei. Autoimmune retinopathy in patients with myasthenia gravis: cases series and literature review. BMC Ophthalmology, Sep 2025. URL: https://doi.org/10.1186/s12886-025-04357-5, doi:10.1186/s12886-025-04357-5. This article has 0 citations and is from a peer-reviewed journal.
(kalogeropoulos2025diagnosisandtreatment pages 22-23): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.
(kalogeropoulos2025diagnosisandtreatment pages 7-8): Dimitrios Kalogeropoulos, Andrew John Lotery, Carlos Pavesio, Chris Kalogeropoulos, Panagiotis Kanavaros, Farid Afshar, Fatima Shawkat, and Gabriella De Salvo. Diagnosis and treatment of autoimmune retinopathy: review of current approaches. International ophthalmology, 45 1:341, Aug 2025. URL: https://doi.org/10.1007/s10792-025-03696-y, doi:10.1007/s10792-025-03696-y. This article has 7 citations and is from a peer-reviewed journal.